The correlation between mediastinal lymphadenopathy positivity proved by mediastinoscopy and serum levels of vascular endothelial growth factor (VEGF) and carcinoembryonic antigen (CEA) in NSCLC cases
B. Kocar, K. Murat, T. Huseyin Cem, E. Artan, T. Karadeli, O. Hayati, S. Cikrikcioglu (Istanbul, Turkey)
Source: Annual Congress 2007 - Diagnosis of thoracic malignancies
Session: Diagnosis of thoracic malignancies
Session type: Thematic Poster Session
Number: 3876
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Kocar, K. Murat, T. Huseyin Cem, E. Artan, T. Karadeli, O. Hayati, S. Cikrikcioglu (Istanbul, Turkey). The correlation between mediastinal lymphadenopathy positivity proved by mediastinoscopy and serum levels of vascular endothelial growth factor (VEGF) and carcinoembryonic antigen (CEA) in NSCLC cases. Eur Respir J 2007; 30: Suppl. 51, 3876
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Serum carcinoembryonic antigen (CEA) level as a predictive marker for distant metastasis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002
Prognostic significance of three tumor markers (CA125, CEA, and TPA) in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Carcinoembryonic antigen mRNA analysis detects micrometastatic cells in blood from lung cancer patients Source: Eur Respir J 2003; 22: 418-421 Year: 2003
Vascular endothelial growth factor (VEGF) expression in non small cell lung cancer and its association with histopathologic type, stage, lymphnode involvement, recurrence and distant metastasis Source: Eur Respir J 2003; 22: Suppl. 45, 393s Year: 2003
Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Prognostic and predictive value of cytokeratin-19 fragments (Cyfra 21-1), carcinoembryonic antigen (CEA) and human chorionic gonadotropin (bHCG) in 138 NSCLC patients - 5 years of observation Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001
Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt-1, VEGF-R2-KDR/Flk-1) as prognostic indicators in small cell lung carcinomas (SCLC) Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Neuron-specific enolase (NSE) serum level as a prognostic factor for tumor regression and survival in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
The elevation serum napsin A in primary lung adenocarcinoma, compared with CEA Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005
The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Investigating new prognostic crossroads in lung carcinomas; comparing the prognostic potential of vascular endothelial growth factor (VEGF) and its receptors versus endoglin (CD105) Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Diagnostic value of linear combination of CYFRA 21-1 and carcinoembryonic antigen in malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004